- Home
- Publications
- Publication Search
- Publication Details
Title
Pathology in drug discovery and development
Authors
Keywords
-
Journal
JOURNAL OF PATHOLOGY
Volume 232, Issue 2, Pages 99-102
Publisher
Wiley
Online
2013-10-12
DOI
10.1002/path.4290
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Developing biomarkers to predict benefit from HGF/MET pathway inhibitors
- (2013) Hartmut Koeppen et al. JOURNAL OF PATHOLOGY
- A matrix approach to guide IHC-based tissue biomarker development in oncology drug discovery
- (2013) Neil R Smith et al. JOURNAL OF PATHOLOGY
- Epistatic interactions and drug response
- (2013) Britta Weigelt et al. JOURNAL OF PATHOLOGY
- The impact of germline mutations on targeted therapy
- (2013) Simon A Smith et al. JOURNAL OF PATHOLOGY
- Pathology is a necessary and informative tool in oncology clinical trials
- (2013) Iris D Nagtegaal et al. JOURNAL OF PATHOLOGY
- Implications of intratumour heterogeneity for treatment stratification
- (2013) Andrew Crockford et al. JOURNAL OF PATHOLOGY
- Dendritic cells in IBD pathogenesis: an area of therapeutic opportunity?
- (2013) Jennifer Bates et al. JOURNAL OF PATHOLOGY
- Molecular pathology and prostate cancer therapeutics: from biology to bedside
- (2013) Daniel Nava Rodrigues et al. JOURNAL OF PATHOLOGY
- Somatic alterations as the basis for resistance to targeted therapies
- (2013) Brian G Blair et al. JOURNAL OF PATHOLOGY
- The genetic complexity of common cancers and the promise of personalized medicine: is there any hope?
- (2013) Monica Arnedos et al. JOURNAL OF PATHOLOGY
- Mouse tumour models to guide drug development and identify resistance mechanisms
- (2013) Meghna Das Thakur et al. JOURNAL OF PATHOLOGY
- The evolving genomic classification of lung cancer
- (2013) David S Shames et al. JOURNAL OF PATHOLOGY
- Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes
- (2013) Brian D Lehmann et al. JOURNAL OF PATHOLOGY
- Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours
- (2013) Jérôme Galon et al. JOURNAL OF PATHOLOGY
- Using the molecular classification of glioblastoma to inform personalized treatment
- (2013) Adriana Olar et al. JOURNAL OF PATHOLOGY
- New drug targets in metastatic melanoma
- (2013) Blanca Homet et al. JOURNAL OF PATHOLOGY
- Mechanisms of age-related macular degeneration and therapeutic opportunities
- (2013) Menno van Lookeren Campagne et al. JOURNAL OF PATHOLOGY
- Biomarkers of drugs targeting HER-family signalling in cancer
- (2013) Filippo Montemurro et al. JOURNAL OF PATHOLOGY
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Development and Use of Integral Assays in Clinical Trials
- (2012) R. L. Schilsky et al. CLINICAL CANCER RESEARCH
- Quality really matters: the need to improve specimen quality in biomedical research
- (2012) Daniel Simeon-Dubach et al. JOURNAL OF PATHOLOGY
- Foundation Medicine
- (2012) Michael Eisenstein NATURE BIOTECHNOLOGY
- Pathological Complete Response and Accelerated Drug Approval in Early Breast Cancer
- (2012) Tatiana M. Prowell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice
- (2011) L. V. Sequist et al. ANNALS OF ONCOLOGY
- Preparing pathology for personalized medicine: possibilities for improvement of the pre-analytical phase
- (2011) Patricia J T A Groenen et al. HISTOPATHOLOGY
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing
- (2011) Nikhil Wagle et al. Cancer Discovery
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- (2010) Gideon Bollag et al. NATURE
- Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
- (2008) Giorgio Vittorio Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- A mouse model for EML4-ALK-positive lung cancer
- (2008) M. Soda et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started